Latest News and Press Releases

ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US AstraZeneca today announced that it has completed its agreement with Perrigo Company plc for the divestment of US rights...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.  THIS ANNOUNCEMENT...

AstraZeneca PLC ("AstraZeneca", "the Company") will today host a conference call for investors and analysts. This will focus on key potential medicines within the late-stage pipeline and will provide...

ASTRAZENECA ENTERS INTO AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US Divestment  further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in...

TAGRISSO™ (AZD9291) APPROVED BY THE US FDA FOR patients with EGFR T790M mutation -positive METASTATIC non-small cell lung cancer One of fastest development programmes - from start of clinical trials...

AstraZeneca PLC announces that yesterday it conducted a global bond market transaction by issuing a total of $6bn of notes. The proceeds of the issue will be used to fund the previously announced...

5 November 2015 Year-To-Date and Q3 2015 Results Financial Summary YTD   2015 Q3   2015 $m %   change $m %   change ...

AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review Acquisition expected to contribute...

Utvecklingen i sammandrag +----------------------+--------+------+---------++--------+------+-------+ | |Första nio månaderna 2015|| Tredje kvartalet 2015...

Tomorrow, Thursday, 5th November 2015, AstraZeneca PLC will release year-to-date and Q3 results for 2015 at 07:00 GMT. An analyst presentation of the year to date and Q3 results for 2015 will...